Successful targeted therapies for hepatocellular carcinoma: Are we really getting there?

Expert Review of Anticancer Therapy

Volumn 8, Issue 4, 2008, Pages 499-505

  Zhu, Andrew X ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CYTOTOXIC AGENT; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; NEVAXAR; OXALIPLATIN; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN INHIBITOR; VATALANIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER MORTALITY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; FATIGUE; HAND FOOT SYNDROME; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; INOPERABLE CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; LIVER TUMOR; METABOLISM; MULTIMODALITY CANCER THERAPY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 43049179757     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.4.499     Document Type: Editorial

References (52)

1. Llovet J, Ricci S, Mazzaferro, V et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). J. Clin. Oncol. 25(18 Suppl.), LBA1 (2007) (Abstract).
2. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Ontologist 11 (7), 790-800 (2006).
3. Huang M, Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett. 135(1), 97-105 (1999).
4. Kato A, Miyazaki M, Ambiru S et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J. Surg. Oncol. 78(2), 110-115 (2001).
5. Kuo MT, Zhao JY, Teeter LD, Ikeguchi M, Chisari FV. Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth Differ. 3(8), 531-540 (1992).
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
7. Sheu JC. Molecular mechanism of hepatocarcinogenesis. J. Gastroenterol. Hepatol. 12(9-10), S309-S313 (1997).
8. Bergsland EK. Molecular mechanisms underlying the development of hepatocellular carcinoma. Semin. Oncol. 28(5), 521-531 (2001).
9. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31(4), 339-346 (2002).
10. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J. Clin. Oncol. 23(31), 8093-8108 (2005).
11. Carlomagno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 98(5), 326-334 (2006).
12. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099-7109 (2004).
13. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoprosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66(24), 11851-11858 (2006).
14. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(26), 4293-4300 (2006).
15. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112(2), 250-259 (2008).
16. Miura H, Miyazaki T, Kuroda M et al. Increased eypression of vascular endothelial growth factor in human hepatocellular carcinoma. J. Hepatol. 27(5), 854-861 (1997).
17. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28(1), 68-77 (1998).
18. Yamaguchi R, Yano H, Nakashima Y et al. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol. Rep. 7(4), 725-729 (2000).
19. Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J. Clin. Pathol. 57(8), 867-871 (2004).
20. Chao Y, Li CP, Chau GY et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol. 10(4), 355-362 (2003).
21. Jeng KS, Sheen IS, Wang YC et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma; a prospective study. World J. Gastroenterol. 10(5), 643-648 (2004).
22. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 91(10), 1354-1360 (2004).
23. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315(3), 971-979 (2005).
24. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer 38(Suppl. 5), S3-S10 (2002).
25. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9(1), 327-337 (2003).
26. Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis 20(8), 757-766 (2003).
27. Abrams TJ, Murray LJ, Pesenti E et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with 'standard of care' therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. 2(10), 1011-1021 (2003).
28. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111(9), 1287-1295 (2003).
29. Zhu AX, Sahani DV, di Tomaso E et al. A Phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 25(18 Suppl.), 4637 (2007) (Abstract).
30. Faivre SJ, Raymond E, Douillard J et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J. Clin. Oncol. 25(18 Suppl.), 3546 (2007).
31. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
32. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7(9), 987-989 (2001).
33. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10(2), 145-147 (2004).
34. Schwartz JD, Schwartz M, Lehrer D et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J. Clin. Oncol. 24(18 Suppl.), 4144 (2006).
35. Malka D, Dromain C, Farace F et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC), Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J. Clin. Oncol. 25(18 Suppl.), 4570 (2007).
36. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabin and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(12), 1898-1903 (2006).
37. Sun W, Haller DG, Mykulowycz K et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC). A Phase II study. J. Clin. Oncol. 25(18 Suppl.), 4574 (2007).
38. Hsu C, Yang T, Hsu C et al. Modified-dose capecitabine + bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC), a Phase II, single-arm study. J. Clin. Oncol. 25(18 Suppl.), 15190 (2007).
39. Thomas MB, Chadha R, Iwasaki M, Glover K, Abbruzzese JL. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 25(18 Suppl.), 4567 (2007) (Abstract).
40. Kira S, Nakanishi T, Suemori S, Kitamoto M, Watanabe Y, Kajiyama G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 17(4), 177-182 (1997).
41. Kiss A, Wang NJ, Xie JP, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-β receptor type II, and p53 expression in human hepatocellular carcinomas. Clin. Cancer Res. 3(7), 1059-1066 (1997).
42. Harada K, Shiota G, Kawasaki H. Transforming growth factor-α and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 19(4), 318-325 (1999).
43. Ito Y, Takeda T, Higashiyama S et al. Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol. Rep. 8(4), 903-907 (2001).
44. Carlin CR, Simon D, Mattison J, Knowles BB. Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines. Mol. Cell Biol. 8(1), 25-34 (1988).
45. Yeh YC, Tsai JF, Chuang LY et al. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res. 47(3), 896-901 (1987).
46. Philip PA, Mahoney MR, Allmer C et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 23(27), 6657-6663 (2005).
47. Thomas MB, Chadha R, Glover K et al. Phase II study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110(5), 1059-1067 (2007).
48. O'Dwyer PJ, (Giantonio BJ, Levy DE, Kauh JS, Fitzgerald DB, Benson AB III. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. J. Clin. Oncol. 24(18 Suppl.), 4143 (2006).
49. Ramanathan RK, Belani CP, Singh DA et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J. Clin. Oncol. 24(18 Suppl.), 4010 (2006).
50. Zhu AX, Stuart K, Blaszkowsky LS et al. Phase II study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110(3), 581-589 (2007).
51. Gruenwald V, Wilkens L, Gebel M et al. A Phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results. J. Clin. Oncol. 25(18 Suppl.), 4598 (2007).
52. Louafi S, Hebbar M, Rosmorduc O et al. Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC), results of the Phase II study ERGO. J. Clin. Oncol. 25(18 Suppl.), 4594 (2007).